CRL
Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.CRL

233.41USD
-0.08%
Nov 08, 2026
CRL overview ready
The chart confirms it.
This is what Trading Compass has established for Charles River Laboratories International, Inc. so far; the remaining research is not yet available.
Theme not measured
No economic group is assigned yet.
Advancing price action
Longer-term context reads early trend, with a near-term setup of daily advance.
Valuation not measured
Fundamentals not measured
Market Jul 13Filing Sep 26Price action Jul 13

Conviction Level

Theme Momentum has no canonical measurement for this company — a research-profile dimension, not an input to this score.

PriceAction7.5BusinessPerformance5.0BusinessQuality7.2Valuation—ThemeMomentum—Mixed — Revenue fell 2% year over year in the latest quarter. Reported earnings improved faster than operating income, so most of the improvement did not come from operations. — From filed financial statements. Describes the recent trajectory of the business, not the stock. 20 of the 100 Conviction points.

Conviction uses Price Action, Business Performance, Business Quality, Valuation. Theme Momentum is research context, not an input.

Theme momentumPrimary theme · group context, not entry timing
No economic group yet — pending research
Price
Loading price history…

Price Action

Advancing price action
Longer-term context reads early trend, with a near-term setup of daily advance.

Key Financials

Market Cap
$11.2B
Avg Volume (60D)
878.4K
60 sessions
Revenue Growth YoY
-0.9%
FY2025 vs FY2024
Operating Margin
+4.0%
Trailing twelve months
Free Cash Flow Yield
+3.6%
P/E
278.3x
EV / EBITDA
30.2x
EV / Sales
3.4x
Market metrics as of Jul 13, 2026
Financial results for the period ended Sep 26, 2026
Filed balance-sheet data as of Sep 26, 2026

Business Performance

Mixed

Revenue fell 2% year over year in the latest quarter. Reported earnings improved faster than operating income, so most of the improvement did not come from operations.

Latest reported: Q3 FY2026, ended Sep 26
Revenue growthDeclining
-2.2%
$983M in Q3 FY2026 · YoY
YoY growth, last 4 quarters
  1. -0.8%
  2. +1.2%
  3. -2.7%
  4. -2.2%
Earnings growthGrowing
+524%
Diluted EPS $6.86 vs $1.10 a year earlier · GAAP
Too few comparable EPS quarters: a loss or a turn to profit has no meaningful percentage.
Operating marginExpanding
20.6%
+7.3 pp YoY
Earnings improved more than operations did

Business Quality

7.2 / 10

How well the business earns on its assets, converts earnings to cash and funds itself — read from its SEC filings.

Fundamentals & Valuation

No valuation has been published for this company yet.

Company Research

Research coverage for this company is in progress.

Economic classification

Loading the economic classification…

Business & Markets

No company profile has been published for this ticker yet.